Eli Lilly hiked its revenue growth guidance by 7%, while Novo Nordisk was forced to slash its targets by ~12%. See why I'm still bullish on LLY stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback